Pharmaceutical Leadership in the AI Era: The Hard Decisions Nobody Is Asking You to Make Yet
Pharmaceutical leadership in the AI era looks deceptively similar to the leadership work of the last decade until you look closely at the decisions actually being made and the decisions being deferred. The visible decisions, which AI vendor to deploy, which platform to standardize on, and which efficiency targets to set, are mostly being made on time. The harder decisions, the ones that will define which pharma firms still exist as independent companies in 2030 and which have been absorbed into larger acquirers, are mostly being deferred. The deferral is invisible from inside the firm and structured over a five-year horizon.
Talk to pharma CEOs who are awake to the trajectory, and a version of the same observation surfaces. The technology decisions are tractable because vendors quantify them, and procurement is built to evaluate them. The leadership decisions are intractable because the existing measurement frame does not capture them, and the existing executive coaching infrastructure does not address them. The result is firms that have made the visible decisions and are sitting on the harder ones because no one has yet forced the question.
Pharmaceutical leadership in the AI era is fundamentally a leadership challenge with a technology component, not the other way around. The firms that recognize the inversion will lead the industry through the next decade. The firms that maintain the inverted framing will deploy excellent AI stacks and find themselves commoditized within five years, compared with firms that decided the harder leadership questions early.
KEY TAKEAWAYS
- Pharmaceutical leadership in the AI era is a leadership challenge with a technology component, not the reverse. Most firms have it inverted.
- The visible decisions about AI tooling are mostly being made on time. The harder leadership decisions are mostly being deferred.
- The next 24 months will define which pharma firms still exist as independent companies in 2030 and which become acquisition targets.
- The career ladder built on the routine analytical tier AI just absorbed is collapsing. Firms that redesign now will have bench depth in 2030.
- Compensation structures that reward throughput are increasingly rewarding work AI just commoditized. Compensation has to evolve.
- The executive capability gap is widening at the same rate the research capability gap is widening, often faster because executive education does not target it.
- The middle position, an undifferentiated mid-cap pharma firm with no clear strategy, is the position that gets acquired at unfavorable valuations.
The Decisions Pharma Leadership Is Deferring
The decisions being deferred at most pharma firms are not the obvious ones. The obvious decisions are getting made. The deferred decisions sit in the harder territory where the existing measurement frame does not provide cover, and the existing infrastructure does not provide a playbook.
How does the firm restructure the researcher career ladder when the routine-analytical-tier AI is absorbed and no longer produces the talent pipeline?
How does the firm compensate for capabilities that the existing metrics do not capture?
Which therapy areas does the firm defend and which does it exit before the market exits them?
What is the firm’s strategic position relative to consolidation, and is the firm preparing to be a strategic acquirer, a favorable acquisition target, or an independent specialist?
Each of these decisions is hard because the answer requires forecasting the industry five and ten years out, accepting that the existing measurement frame does not yet validate the decision, and committing to investments that produce no return for eighteen months. Each also defines the firm’s position in 2030, whether the leadership team makes the decision deliberately or defaults into it by deferring. Pharmaceutical leadership in the AI era is the discipline to make these decisions deliberately, rather than letting them be made by drift.
The pharma firms that make these decisions in the next twenty-four months will look fundamentally different by 2030. The firms that defer will be making the same decisions in 2030 from a position of weakness. The window for deliberate strategic positioning is open right now, and it narrows as the consolidation accelerates and the capability gap between leading and lagging firms widens.
The decisions being deferred are the ones that define the firm in 2030. Defer them long enough and they get made by drift, usually in the wrong direction.
Sylvie di Giusto
Redesigning the Researcher Career Ladder
The researcher’s career ladder, as it existed five years ago, no longer maps to where the work is going, and the redesign is one of the most pressing leadership decisions on the table. The traditional pipeline assumed an entry-level analytical tier that handled screening, literature review, and standard analytical execution while building the institutional knowledge to grow into senior researcher and program lead roles. AI has absorbed most of that work over the last few years, and the pace of absorption is accelerating. The pipeline is hollowing out from the bottom, and the firms that have not redesigned it are operating on a model that no longer supports the underlying work.
Redesigning the ladder requires three concrete moves. New entry points that bypass the obsolete routine tier and place new researchers directly into the human capability stack work, paired with experienced researchers who teach the AI literacy, regulatory science, and trial adaptation work that compounds. New career paths that compound on differentiated capability rather than throughput. New advancement criteria that reward the work AI cannot do, with the metrics deliberately designed for that purpose. None of this is fast, and none of it can be deferred without consequence.
Pharmaceutical leadership in the AI era requires a commitment to this redesign over the next 12 months. The firms that begin now will have bench depth in 2030 because the differentiated researchers they developed will have compounded for years. The firms that wait will face a bench-depth crisis in 2030 because the talent pipeline will have run dry, failing to produce the differentiated capability the era requires.
The career ladder you inherited assumed a routine analytical tier the AI just hollowed out.
Sylvie di Giusto
Compensation That Rewards the Work AI Cannot Do
Compensation is the second area in which pharmaceutical leadership in the AI era requires hard decisions that the existing framework does not address. Most pharma compensation structures still reward throughput, the volume of candidates screened, the number of literature reviews completed, or the speed of standard analytical execution. AI absorbed most of that work, and the structures are now rewarding work that the technology just commoditized. The researchers were heavily compensated for analytical throughput and are being compensated for work that no longer differentiates the firm.
Redesigning compensation is harder than redesigning the career ladder because compensation is contractually entangled and culturally entrenched. But the redesign is unavoidable. The firms that get there first will attract the researchers building the differentiated capability stack because those researchers will go where the compensation reflects what they actually do. The firms that defer will lose those researchers to firms that designed compensation around the work era, which is rewarding.
The redesign does not have to be radical to start. Introducing a meaningful share of compensation tied to capability development and differentiated program outcomes, rather than purely to throughput, signals where the firm is heading and lays the cultural groundwork for deeper redesign over two to three years. Pharmaceutical leadership in the AI era requires beginning this redesign now, not when the talent flight makes it urgent and reactive.
Compensation built on analytical throughput is increasingly rewarding work AI just commoditized. The redesign cannot wait for the talent flight to make it urgent.
Sylvie di Giusto
The Executive Capability Stack
Pharmaceutical leadership in the AI era requires the executive layer to build the same capability stack the research workforce needs, plus the leadership capabilities to deploy it organizationally. AI literacy at the executive level. Regulatory science fluency at strategic depth. Real-world evidence and digital biomarker fluency. Moral framing for the harder strategic decisions about which programs to advance, which therapy areas to exit, and which capabilities to invest in.
The executive capability gap is, in some ways, further along than the research gap because the existing executive education infrastructure does not target it. Industry conferences cover trends rather than build capability. MBA programs target it generically rather than specifically. Executive coaching focuses on leadership style rather than on industry-specific capabilities. The result is an executive layer that is increasingly under-equipped to lead the firm through the era in which it now operates. Not because the executives are insufficient, but because the development infrastructure was built for a previous era.
Three deliberate moves pharma executives can make in the next twelve months to begin closing the executive capability gap:
Commit to one or two FDA, EMA, or institutional regulatory science publications per quarter. Personal capability building, not delegated to staff.
Schedule one quarterly conversation with an adjacent specialist outside traditional pharma. AI explainability researcher, patient advocacy lead, real-world evidence analyst, or digital health entrepreneur. The exposure compounds.
Read one book per quarter on systems thinking applied to organizational and strategic decision-making. The discipline reshapes how the firm is led over the years.
None of this requires a sabbatical or executive program enrollment. However, all of it provides the compounding capability that the next decade of pharma leadership will require, but that the previous decade did not.
The development infrastructure for executives was built for a previous era and no one is yet asking you to close the gap.
Sylvie di Giusto
Strategic Positioning in a Consolidating Market
The pharma industry is consolidating at a pace that makes strategic positioning one of the most consequential decisions on the table, particularly in mid-cap pharma and biotech. The consolidation favors firms with operational scale and firms with differentiated capability advantages. The middle position, an undifferentiated mid-cap firm without a clear strategic identity, is the position that gets acquired at unfavorable valuations. The consolidation does not pause for firms that have not yet decided their position.
Pharmaceutical leadership in the AI era requires deciding deliberately, now, whether the firm is positioning itself as a strategic acquirer building scale, a strategic acquisition target at favorable valuations because of differentiated capabilities, or an independent specialist. The answer to that question shapes which workforce capabilities you build and which you acquire through talent or deals. Each path requires different investments, different leadership focus, and different timelines.
The decision is not easy because each path has real costs and real risks, and the outcome will not be visible for several years. But the decision being deferred is itself a decision, and the deferred decision is almost always the unfavorable acquisition outcome. Pharma CEOs who recognize this and drive the strategic conversation will produce better outcomes than CEOs who defer until consolidation pressure forces the decision under unfavorable conditions.
The consolidation does not pause for firms that have not yet decided their position.
Sylvie di Giusto
The Conversations Pharma Boards Should Be Having
Pharma board conversations matter here because the leadership decisions described above require board alignment that does not happen automatically. Most pharma boards are still focused on the visible metrics, pipeline progression, regulatory milestones, or peak sales projections that the existing measurement frame produces. The harder strategic conversations about career ladder redesign, compensation evolution, executive capability development, and consolidation positioning often do not happen at most boards because the board agenda has not kept pace with the era.
Pharma CEOs reading this should be the ones forcing those conversations onto the board agenda in the next months. The board that is having those conversations now will support the leadership decisions the era requires. The board that is not will resist them when they come and do so long enough that the firm falls into an unfavorable strategic position by default. Pharmaceutical leadership in the AI era requires the CEO to be the one to put the harder questions in front of the board before they become urgent and reactive.
The CEO who forces these harder conversations onto the board is the CEO who keeps the firm strategically positioned through the decade.
Sylvie di Giusto
What the Next Twelve Months Should Look Like
For pharma CEOs and senior leaders reading this, the practical question is what the next twelve months should actually look like. Three concrete moves matter most.
First, force the deferred decisions onto the executive agenda in the next quarter, with explicit deadlines for resolution, including career ladder redesign, compensation evolution, and consolidation positioning.
Second, begin the personal executive development work, not delegated, on the capabilities AI is absorbing and the judgment it cannot replace, on a quarterly cadence.
Third, force the harder strategic conversations onto the board agenda over the next two to three board meetings.
Twelve months is enough time to begin all three. The firms where leadership begins all three in the next twelve months will be visibly different by 2030 and structurally differentiated. The firms that defer will be operating on a model that the era no longer supports, with leadership decisions made by drift rather than design, and outcomes that reflect that drift. The choice is binary, and it is being made right now whether the leadership team realizes it or not.
Defer them and the decisions still get made, just by drift, almost always in the wrong direction.
Sylvie di Giusto
Pharmaceutical leadership in the AI era is a leadership challenge with a technology component, not the reverse. The firms that recognize the inversion early and lead from that recognition will define the industry through the next decade. The firms that maintain the inverted framing, treating AI as primarily a technology problem and deferring the harder leadership decisions, will deploy excellent AI stacks and find themselves commoditized within five years against firms that decided the harder questions early.
The next twenty-four months are the strategic window. The decisions made in that window, whether deliberate or by deferral, will determine which pharma firms exist as independent companies in 2030 and which are absorbed by larger acquirers. Pharma CEOs who treat this as the leadership challenge it is, who force the harder conversations onto the executive and board agenda, who begin the executive capability work personally rather than delegating it, will produce outcomes that reflect their leadership. CEOs who do not will produce outcomes that reflect the drift. The strategic positioning is being decided right now.
Frequently asked questions
What should pharma firm CEOs be deciding in the next twenty-four months about AI?
The decisions that matter most are not the visible ones about which AI tools to deploy. Those decisions are mostly already made. The decisions that will define the firm in 2030 are the harder ones nobody is yet pressuring you to make. How to redesign the researcher and clinical operator career ladder when the routine tier the AI absorbed no longer produces the talent pipeline. How to fund human capability development that produces no return for eighteen months. How to compensate for capabilities the existing measurement frame does not capture. How to decide which therapy areas to defend and which to exit. Pharmaceutical leadership in the AI era is defined by the decisions made when no one is yet asking you to make them.
How should pharma firm leadership respond to the consolidation pressure?
The consolidation pressure is real and accelerating, particularly in mid-cap pharma and biotech. It favors firms that built differentiated capability and firms with operational scale advantages. Firms that built neither become acquisition targets at unfavorable valuations. Pharmaceutical leadership in the AI era requires deciding deliberately whether the firm is positioning to be a strategic acquirer, a strategic acquisition target at favorable valuations, or an independent specialist with deep enough capability advantage to remain independent.
What capabilities should pharma leadership teams be building in themselves?
Pharma executives need the same capability stack the research workforce needs, plus the leadership capabilities to deploy it organizationally. AI literacy at the executive level. Regulatory science fluency at strategic depth. Real-world evidence and digital biomarker fluency. Moral framing for the harder strategic decisions about which programs to advance and which to retire. The leadership capability gap is widening at the same rate the research capability gap is widening, often faster because executive education does not target it.
Pharma CEOs book Forever Human when the executive team needs the deferred leadership decisions made visible in a single room. Explore the keynote that machines will never deliver.
Sylvie di Giusto is an International Hall of Fame keynote speaker who works with executive audiences across industries on the leadership decisions that determine which firms thrive through structural disruption. Her “Forever Human” series projects the trajectory of major industries by 2050 and examines what pharma and industry leaders should be deciding right now to define the next decade.
If your pharma executive team, board, or industry leadership conference would benefit from a keynote on the leadership decisions that define pharmaceutical success in the AI era, the conversation starts at sylviedigiusto.com/contact.
